Enalapril

also known as enalapril maleate · Corodil · Enalapril "ratiopharm" · Epaned · Vasotec

Other / unclassified targets ACE via inhibition

Developed for: hypertensive disorder · heart failure · cardiovascular disorder · diabetic kidney disease · dilated cardiomyopathy · essential hypertension · heart disorder · preeclampsia
+41 more
· breast cancer · chemotherapy-induced toxicity · COVID-19 · IgA glomerulonephritis · type 2 diabetes mellitus · atherosclerosis · cancer · Chagas cardiomyopathy · congenital heart disease · congenital vascular malformation · diabetes mellitus · diastolic heart failure · erectile dysfunction · hypertension, pregnancy-induced · intracerebral hemorrhage · mild heart failure · moderate heart failure · muscular dystrophy · myocardial disorder · non-Hodgkin lymphoma · pneumonia · poisoning · proteinuria · pseudohypoaldosteronism · retinal ischemia · rheumatoid arthritis · sickle cell disease · symptomatic heart failure · type 1 diabetes mellitus · Barrett esophagus · Chagas disease · chronic kidney disease · complement 3 glomerulopathy · congestive heart failure · puerperal disorder · radiation pneumonitis · resistant hypertension · secondary hypertension · severe pre-eclampsia · ST-elevation myocardial infarction · systolic heart failure
Investigated by: National Heart, Lung, and Blood Institute (NHLBI) · Novartis Pharmaceuticals · Ethicare GmbH · Duke University · European Institute of Oncology · Federal University of Minas Gerais
+88 more
· Hospital de Clinicas de Porto Alegre · National Center for Research Resources (NCRR) · Tehran University of Medical Sciences · University of Copenhagen · University of Sao Paulo · Assistance Publique - Hôpitaux de Paris · Assiut University · Astellas Pharma Inc · Australian and New Zealand Intensive Care Research Centre · Berry Consultants · Bispebjerg Hospital · Boehringer Ingelheim · Canadian Institutes of Health Research (CIHR) · Children's Oncology Group · Dexcel Pharma Technologies Ltd. · European Commission · European Union · GlaxoSmithKline · Global Coalition for Adaptive Research · Göteborg University · Haukeland University Hospital · Hospital Arnau de Vilanova · Hospital Britanico · Hospital Clinic of Barcelona · InCor Heart Institute · Instituto de Salud Carlos III · Intensive Care National Audit & Research Centre · Istituto Auxologico Italiano · Italian Society of General Practitioners · Italian Society of Hypertension · Manchester University NHS Foundation Trust · Martin Huelsmann · Masonic Cancer Center, University of Minnesota · Medical Research Institute of New Zealand · Medical University of Vienna · Meir Medical Center · Mental Health Centre Sct. Hans (Denmark) · Merck Frosst Canada Ltd. · Merck Sharp & Dohme LLC · Methodist Hospital Foundation · Michael Mauer, MD · Nat Intensive Care Surveillance - MORU · National Cancer Institute (NCI) · National Cheng-Kung University Hospital · National Health Security Office, Thailand · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National University Hospital, Singapore · Nebraska Methodist Health System · Newcastle University · Newcastle-upon-Tyne Hospitals NHS Trust · Norwegian Cancer Society · Oslo University Hospital · Ottawa Heart Institute Research Corporation · Penn State University · Pfizer · RECORDATI GROUP · Ramathibodi Hospital · Shahid Beheshti University of Medical Sciences · Shiraz University of Medical Sciences · South Tees Hospitals NHS Foundation Trust · St George's, University of London · St. Marianna University School of Medicine · Stanford University · São Paulo Research Foundation · Tanta University · The Cleveland Clinic · The Government Pharmaceutical Organization · The Leiden Academic Center for Drug Research (LACDR) · The Ministry of Science, Technology and Innovation, Denmark · The Norwegian Melanoma Group · UMC Utrecht · Ubon Ratchathani Public Health Office, Thailand · Unidad de Investigacion Medica en Enfermedades Renales · Unity Health · all 94 on the full record

Regulatory milestones approvals, filings & regulatory actions · 8 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Aqumeldi	—	2023-11-15	europa.eu ↗
Label expansion	US (FDA)	EPANED KIT	—	2014-09-04	fda.gov ↗
Label expansions (5)	US (FDA)	VASOTEC	—	1988-06-24 – 2001-02-13	fda.gov ↗
Approved	US (FDA)	VASOTEC	—	1985-12-24	fda.gov ↗

Trials 64 · started per year

today

US approved 1985

EU approved 2023

19851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT02252692	Aug → Oct 2014	heart failure	Ethicare GmbH	Unknown	No outcome recorded
Phase 1	NCT01822639	Apr → May 2013	hypertensive disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01117038	Apr → May 2010	erectile dysfunction	VIVUS LLC	Completed	No outcome recorded
Phase 1	NCT01115946	Mar → Apr 2010	—	Astellas Pharma Inc	Completed	No outcome recorded
Phase 1	NCT00899587	—	retinal ischemia	Shahid Beheshti University of Medical Sciences	Unknown	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT03179163	Jul 2016 → Aug 2022	essential hypertension	Penn State University	Terminated	No outcome recorded
Phase 213 trials
Phase 2	NCT06788314	Feb 2025 → Dec 2029 expected	congenital vascular malformation	Oslo University Hospital	Recruiting	No outcome recorded
Phase 2	NCT05232370	Jan 2022	—	Unidad de Investigacion Medica en Enfermedades Renales	Completed	No outcome recorded
Phase 2	NCT03466333	Sep 2018 → Sep 2020	preeclampsia	Manchester University NHS Foundation Trust	Completed	No outcome recorded
Phase 2	NCT03005184	Sep 2017 → Jan 2020	mild heart failure, moderate heart failure	Vanderbilt University Medical Center	Withdrawn	No outcome recorded
Phase 2	NCT03667131	Feb → Dec 2017	rheumatoid arthritis	University of Guadalajara	Completed	No outcome recorded
Phase 2	NCT01705392	Jan 2013 → Feb 2017	metastatic melanoma	Haukeland University Hospital	Terminated	No outcome recorded
Phase 2	NCT02281838	Aug 2011 → Nov 2021	intracerebral hemorrhage	University of Alberta	Terminated	No outcome recorded
Phase 2	NCT01093807	Mar 2010 → Mar 2011	essential hypertension	RECORDATI GROUP	Completed	No outcome recorded
Phase 2	NCT00603590	Nov 2006 → Jun 2008	heart disorder, hyperlipidemia, hypertensive disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT00394394	Feb 2005 → ?	hypertensive disorder	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
Phase 2	NCT00143949	Mar 1997 → Mar 2007	type 1 diabetes mellitus	Michael Mauer, MD	Completed	No outcome recorded
Phase 2	NCT00004328	Dec 1992 → ?	pseudohypoaldosteronism	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2	NCT00000522	Aug 1985 → May 1994	heart disorder, hypertensive disorder	University of Minnesota	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT02678312	Nov 2016 → Jan 2022	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2/3	NCT02654678	Mar 2016 → Apr 2018	congenital heart disease, dilated cardiomyopathy, heart failure	Ethicare GmbH	Unknown	No outcome recorded
Phase 2/3	NCT02652728	Jan 2016 → Jun 2017	dilated cardiomyopathy, heart failure	Ethicare GmbH	Unknown	No outcome recorded
Phase 316 trials
Phase 3	NCT07222852	Nov 2025 → Oct 2027 expected	preeclampsia	Women and Infants Hospital of Rhode Island	Not yet recruiting	No outcome recorded
Phase 3	NCT04591210	Jan 2021 → Dec 2024	COVID-19, cardiovascular disorder	Ottawa Heart Institute Research Corporation	Completed	No outcome recorded
Phase 3	NCT04345406	Apr 2020 → Dec 2029 expected	COVID-19	Tanta University	Not yet recruiting	No outcome recorded
Phase 3	NCT03265574	Oct 2017 → Aug 2023	breast cancer, non-Hodgkin lymphoma	South Tees Hospitals NHS Foundation Trust	Completed	No outcome recorded
Phase 3	NCT03066804	Aug 2017 → Oct 2019	diastolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	No outcome recorded
Phase 3	NCT03459560	Dec 2015 → Mar 2022	cardiovascular disorder	Tehran University of Medical Sciences	Unknown	No outcome recorded
Phase 3	NCT01968200	Dec 2012 → Dec 2019	cancer	European Institute of Oncology	Unknown	No outcome recorded
Phase 3	NCT02432885	Jun 2009 → Jun 2012	cardiovascular disorder, muscular dystrophy	InCor Heart Institute	Completed	No outcome recorded
Phase 3	NCT00853658	Mar 2009 → Oct 2015	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01110824	Apr 2008 → Dec 2011	acute myeloid leukemia, plasma cell myeloma, precursor lymphoblastic lymphoma/leukemia	Hospital Clinic of Barcelona	Completed	No outcome recorded
Phase 3	NCT00446511	Jun 2007 → Jun 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00003070	Sep 2000 → Jul 2003	chemotherapy-induced toxicity, childhood malignant neoplasm	Children's Oncology Group	Completed	No outcome recorded
Phase 3	NCT00274118	Jul 1997 → Jan 2004	hypertensive disorder, type 2 diabetes mellitus	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00000547	Apr 1994 → Feb 2001	heart failure, myocardial disorder	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT00000516	Jul 1985 → May 1990	coronary artery disorder, heart failure, hypertensive disorder, myocardial ischemia	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded

Phase 414 trials
Phase 4	NCT07023003	Jul 2025 → Jul 2028 expected	hypertension, pregnancy-induced	Nebraska Methodist Health System	Recruiting	No outcome recorded
Phase 4	NCT05711810	Jan 2023	Orthocoronavirinae infectious disease, myocarditis	Yang I. Pachankis	Completed	No outcome recorded
Phase 4	NCT05637853	Oct 2022 → Aug 2024 overdue	symptomatic heart failure	Göteborg University	Active not recruiting	No outcome recorded
Phase 4	NCT02817360	Feb 2016 → Dec 2025 overdue	heart disorder, type 2 diabetes mellitus	Martin Huelsmann	Recruiting	No outcome recorded
Phase 4	NCT01669434	Jun 2015 → Nov 2016	—	University of Nebraska	Completed	No outcome recorded
Phase 4	NCT02135263	Apr 2012 → May 2014	butyrylesterase 1	Bispebjerg Hospital	Completed	No outcome recorded
Phase 4	NCT01211314	Jan → Dec 2011	hypertensive disorder	Meir Medical Center	Terminated	No outcome recorded
Phase 4	NCT01069042	Feb → Aug 2010	heart failure	National Cheng-Kung University Hospital	Unknown	No outcome recorded
Phase 4	NCT00734123	Apr 2008 → Apr 2009	atherosclerosis	Hospital Arnau de Vilanova	Unknown	No outcome recorded
Phase 4	NCT00456963	Sep 2007 → Mar 2010	diabetes mellitus, hypertensive disorder	Istituto Auxologico Italiano	Terminated	No outcome recorded
Phase 4	NCT00419835	May 2005 → Sep 2007	diabetic kidney disease	University of Sao Paulo	Completed	No outcome recorded
Phase 4	NCT01557140	May 2003 → Mar 2004	Chagas cardiomyopathy, dilated cardiomyopathy, heart failure	Federal University of Minas Gerais	Completed	No outcome recorded
Phase 4	NCT00292526	Nov 2000 → Nov 2011	chemotherapy-induced toxicity	European Institute of Oncology	Completed	No outcome recorded
Phase 4	NCT00367562	Jan 1996 → Dec 2005	IgA glomerulonephritis	Hospital Britanico	Completed	No outcome recorded

Phase not applicable12 trials
—	NCT07363343	Mar 2026 → Dec 2029 expected	preeclampsia	The Cleveland Clinic	Recruiting	No outcome recorded
—	NCT06187493	Jan 2024 → Jan 2025	diabetic kidney disease	Assiut University	Unknown	No outcome recorded
—	NCT06710600	Sep 2022 → Apr 2024	photosensitivity disease	Medical University of Vienna	Completed	No outcome recorded
—	NCT04092309	Sep 2019 → Sep 2020	disease related to hematopoietic stem cell transplant, poisoning	University of Athens	Unknown	No outcome recorded
—	NCT03949075	May → Dec 2019	—	University of Copenhagen	Completed	No outcome recorded
—	NCT01867047	Jun 2013 → Jun 2016	hypotensive disorder	Duke University	Terminated	No outcome recorded
—	NCT01364675	Jan 2012 → Jul 2016	hypertensive disorder, prediabetes syndrome	Ramathibodi Hospital	Unknown	No outcome recorded
—	NCT01096121	Jun 2010 → Jan 2012	sickle cell disease	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
—	NCT00895414	Apr 2009 → Apr 2014	breast cancer	Masonic Cancer Center, University of Minnesota	Completed	No outcome recorded
—	NCT00141583	Apr 2004 → Oct 2006	essential hypertension	St George's, University of London	Terminated	No outcome recorded
—	NCT00484068	Jan 2003 → Jun 2006	diabetic kidney disease, proteinuria	Hospital de Clinicas de Porto Alegre	Completed	No outcome recorded
—	NCT00006137	May 2000 → ?	IgA glomerulonephritis	National Center for Research Resources (NCRR)	Completed	No outcome recorded

Also used as a comparator or background therapy in 69 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT02879721 Comparator	Oct 2009 → Dec 2012	Barrett esophagus	Göteborg University	Completed	No outcome recorded
Phase 12 trials
Phase 1	NCT02623036 Comparator	Nov 2015 → Apr 2018	resistant hypertension	Memorial Health University Medical Center	Unknown	No outcome recorded
Phase 1	NCT00270153 Comparator	Sep 2004 → Dec 2009	—	Montefiore Medical Center	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT01624064 Comparator	Aug → Oct 2012	chronic kidney disease	Ministry of Health, Sri Lanka	Unknown	No outcome recorded
Phase 28 trials
Phase 2	NCT04484350 Background	Oct 2020 → Feb 2023	hypertensive disorder, ischemic stroke, vascular occlusion disorder	Hamilton Health Sciences Corporation	Completed	No outcome recorded
Phase 2	NCT04183101 Comparator	Oct 2020 → Dec 2029 expected	C3 glomerulonephritis, dense deposit disease, membranoproliferative glomerulonephritis	Region Skane	Recruiting	No outcome recorded
Phase 2	NCT01754909 Comparator	Nov 2013 → Apr 2018	lung cancer, radiation pneumonitis	VA Office of Research and Development	Completed	No outcome recorded
Phase 2	NCT00543413 Comparator	Oct 2007 → Jun 2008	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00963976 Background	Jan 2007 → Dec 2011	intracerebral hemorrhage	University of Alberta	Completed	No outcome recorded
Phase 2	NCT00396721 Comparator	Jan 2006 → Oct 2009	IgA glomerulonephritis	Josep m Cruzado	Completed	No outcome recorded
Phase 2	NCT00520247 Background	Sep 2005 → Feb 2006	hyperhomocysteinemia, hypertensive disorder	Anhui Medical University	Completed	No outcome recorded
Phase 2	NCT02088450 Comparator	Feb 1990 → Feb 1997	—	KU Leuven	Terminated	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT05373004 Comparator	Mar 2023 → Mar 2024	diabetic kidney disease	Omar Tarek Elfarargi	Unknown	No outcome recorded
Phase 2/3	NCT02575092 Background	Nov 2015 → Feb 2019	coronary artery disorder, hyperhomocysteinemia, hypertensive disorder	Fuling Central Hospital of Chongqing City	Completed	No outcome recorded
Phase 2/3	NCT01007994 Comparator	Nov 2009 → Jan 2020	secondary hypertension	Northwell Health	Completed	No outcome recorded
Phase 316 trials
Phase 3	NCT04912167 Comparator	Nov 2021 → Mar 2022	ST-elevation myocardial infarction	West China Hospital	Unknown	No outcome recorded
Phase 3	NCT04853758 Comparator	May 2021 → Dec 2024	Chagas cardiomyopathy	University of Sao Paulo General Hospital	Unknown	No outcome recorded
Phase 3	NCT03917459 Comparator	Apr 2019 → May 2021	erectile dysfunction, systolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02900378 Comparator	Dec 2016 → Apr 2018	congestive heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT02468232 Comparator	Jun 2015 → Feb 2019	systolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01437371 Background	Aug 2011 → Jun 2014	heart failure	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 3	NCT01271985 Comparator	Feb 2011 → Jan 2019	cardiovascular disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 3	NCT01151410 Comparator	Aug 2010 → Aug 2015	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01035255 Comparator	Dec 2009 → May 2014	symptomatic heart failure	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 3	NCT00568178 Comparator	Jun 2007 → Sep 2008	proteinuria	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00433836 Comparator	Jan 2007 → Feb 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00113698 Comparator	Dec 2004 → Nov 2005	congestive heart failure, ventricular septal defect	University of Utah	Terminated	No outcome recorded
Phase 3	NCT00113087 Comparator	Aug 2003 → Jul 2008	congenital heart disease, congestive heart failure	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
Phase 3	NCT01411735 Comparator	Jul 2003 → Jun 2004	diastolic heart failure	Wake Forest University	Completed	No outcome recorded
Phase 3	NCT02177448 Comparator	Sep 1998 → Sep 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00882440 Comparator	Dec 1990 → Aug 1991	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Phase 430 trials
Phase 4	NCT07547878 Comparator	Apr 2026 → Mar 2029 expected	chronic kidney disease, type 2 diabetes mellitus	Baylor Research Institute	Not yet recruiting	No outcome recorded
Phase 4	NCT07513883 Background	Mar 2026 → Sep 2028 expected	heart failure	Ziekenhuis Oost-Limburg	Recruiting	No outcome recorded
Phase 4	NCT05487261 Comparator	Dec 2022 → Feb 2025	heart failure	Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań	Unknown	No outcome recorded
Phase 4	NCT04330300 Comparator	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded
Phase 4	NCT04236258 Comparator	Jan 2020 → Jun 2021	puerperal disorder, severe pre-eclampsia	Brigham and Women's Hospital	Completed	No outcome recorded
Phase 4	NCT04023227 Comparator	Dec 2019 → Mar 2025	Chagas disease, heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT03502031 Comparator	Oct 2018 → Oct 2022	diabetic kidney disease	James A. Tumlin, MD	Unknown	No outcome recorded
Phase 4	NCT03472508 Comparator	Mar 2018 → Mar 2019	hypertensive disorder	Shenzhen Ausa Pharmed Co.,Ltd	Unknown	No outcome recorded
Phase 4	NCT03190304 Comparator	Jun 2017 → Sep 2020	heart failure, isoproterenol-mediated vasodilatation	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 4	NCT03119623 Comparator	Jun 2017 → Aug 2019	symptomatic heart failure	Brigham and Women's Hospital	Withdrawn	No outcome recorded
Phase 4	NCT03051282 Comparator	Apr 2017 → Jan 2026	—	University of Michigan	Completed	No outcome recorded
Phase 4	NCT02970669 Comparator	Dec 2016 → Mar 2018	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02874794 Comparator	Aug 2016 → Dec 2018	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02768298 Comparator	Jul 2016 → Nov 2019	symptomatic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02554890 Comparator	Apr 2016 → Jun 2018	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT02817503 Background	Dec 2015 → Dec 2016	hyperhomocysteinemia, hypertensive disorder	Second Affiliated Hospital of Nanchang University	Unknown	No outcome recorded
Phase 4	NCT02214498 Comparator	May 2015 → May 2017	essential hypertension	Erasmus Medical Center	Unknown	No outcome recorded
Phase 4	NCT02200822 Comparator	Jul 2014 → Feb 2019	heart failure	Hasselt University	Completed	No outcome recorded
Phase 4	NCT02571842 Comparator	Jan 2012 → Dec 2016	IgA glomerulonephritis	Chulalongkorn University	Unknown	No outcome recorded
Phase 4	NCT01305850 Comparator	Jul 2010 → Aug 2011	—	Chulalongkorn University	Unknown	No outcome recorded
Phase 4	NCT01041963 Comparator	Jun 2009 → Jun 2010	—	Chulalongkorn University	Unknown	No outcome recorded
Phase 4	NCT00741585 Comparator	Sep 2008 → Jun 2018	chronic kidney disease, essential hypertension, stroke disorder	University of Vigo	Completed	No outcome recorded
Phase 4	NCT01871740 Comparator	May 2008 → Jun 2014	essential hypertension, hyperhomocysteinemia	Shenzhen Ausa Pharmed Co.,Ltd	Withdrawn	No outcome recorded
Phase 4	NCT00794885 Comparator	May 2008 → Aug 2013	essential hypertension	Shenzhen Ausa Pharmed Co.,Ltd	Completed	No outcome recorded
Phase 4	NCT00666848 Comparator	Mar 2008 → Aug 2009	hypertensive disorder, metabolic syndrome X	Vanderbilt University	Completed	No outcome recorded
Phase 4	NCT00391846 Background	Oct 2006 → Jan 2009	left ventricular failure	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00235287 Comparator	Sep 2005 → ?	cardiovascular disorder, chronic kidney disease	Herlev Hospital	Unknown	No outcome recorded
Phase 4	NCT00302705 Comparator	Jan 2005 → Mar 2007	essential hypertension	University of Vigo	Completed	No outcome recorded
Phase 4	NCT02177461 Comparator	Apr 2000 → Aug 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00295542 Comparator	Mar 2000 → Apr 2009	hypertensive disorder	University of Vigo	Completed	No outcome recorded

Phase not applicable8 trials
—	NCT07568574 Background	Mar 2026 → May 2028 expected	—	Enhanced Emirates Limited	Enrolling by invitation	No outcome recorded
—	NCT05479097 Background	Feb → Aug 2023	hypertensive disorder	University of Wisconsin, Madison	Completed	No outcome recorded
—	NCT03526042 Comparator	Sep 2017 → Jul 2019	atherosclerosis, lupus nephritis	National Institute of Medical Sciences and Nutrition Salvador Zubiran	Unknown	No outcome recorded
—	NCT01891292 Comparator	Jul 2013 → Aug 2014	proteinuria, sickle cell disease	The University of The West Indies	Unknown	No outcome recorded
—	NCT01839253 Comparator	Aug 2012 → Mar 2014	—	Yonsei University	Completed	No outcome recorded
—	NCT01015937 Comparator	Mar 2008 → Jun 2009	diabetic kidney disease, proteinuria	Shaheed Faghihi Hospital	Completed	No outcome recorded
—	NCT00292162 Comparator	Jan 2007 → Jul 2009	atrial fibrillation, heart failure	NHS Greater Glasgow and Clyde	Completed	No outcome recorded
—	NCT00684489 Comparator	Sep 2003 → Mar 2005	essential hypertension	Medical University of South Carolina	Completed	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2018-04-04	Novartis Pharmaceuticals	Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril novartis.com ↗
2000-08-23	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Received Two Approvals:Final Approval for Enalapril to be Shipped Immediately Tentative Approval for Loratadine tevapharm.com ↗

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 134 sources stand behind the page.

Field	Value	Cited text
Known as	enalapril	“Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ 129 “In the second week, RAASi will be introduced with either angiotensin converting enzyme inhibitor (ACEi)(Ramipril or Enalapril) or angiotensin receptor neprilisyn inhibitor...” NCT05637853 ↗ “If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.” NCT02088450 ↗ “We randomized 90 patients with preserved left ventricular ejection fraction (LVEF) after BMT to sacubitril/valsartan, enalapril, or no cardioprotective medication (controls).” PMID 39983618 ↗ Feb 2025 “A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily” NCT01271985 ↗ “sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d” NCT00396721 ↗ “RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)” NCT03502031 ↗ “The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril.” NCT04591210 ↗ “The polypill comprises hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg.” PMID 32894967 ↗ Aug 2020 “The combined use of enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke.” NCT02817503 ↗ “Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily” NCT00603590 ↗ “Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril” NCT04330300 ↗ “All patients received enalapril (up-titrated to 20 mg BID) and spironolactone (25 mg QD).” NCT01557140 ↗ “prescription of antihypertensives (amlodipine and/or losartan OR enalapril)” NCT05479097 ↗ “ACE inhibitor: enalapril, lisinopril, ramipril, captopril or trandolapril” NCT07513883 ↗ “enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop” NCT02200822 ↗ “benazepril, captopril, enalapril, fosinopril, lisinopril” NCT00684489 ↗ “Other Name: Enalapril, Lorsartan, Prednisolone” NCT02571842 ↗ “enalapril (Enalapril "ratiopharm") 10mg” NCT06710600 ↗ “Captopril or enalapril” NCT04345406 ↗ “Enalapril 40mg/d” NCT02817360 ↗ “enalapril” NCT01669434 ↗ “Enalapril” NCT01839253 ↗ “Enalapril” NCT00741585 ↗ “Enalapril” NCT02735707 ↗ “Enalapril” NCT05232370 ↗ “enalapril” NCT01015937 ↗ NCT00292162 ↗ NCT03949075 ↗ NCT00794885 ↗ NCT00270153 ↗ NCT00446511 ↗ NCT01411735 ↗ NCT07547878 ↗ NCT02900378 ↗ NCT01069042 ↗ NCT05373004 ↗ NCT01096121 ↗ NCT00292526 ↗ NCT04484350 ↗ NCT00963976 ↗ NCT03119623 ↗ NCT00419835 ↗ NCT00006137 ↗ NCT03466333 ↗ NCT04236258 ↗ NCT02468232 ↗ NCT00899587 ↗ NCT02177448 ↗ NCT00433836 ↗ NCT02652728 ↗ NCT02879721 ↗ NCT03472508 ↗ NCT01624064 ↗ NCT04023227 ↗ NCT01822639 ↗ NCT00295542 ↗ NCT02177461 ↗ NCT00113698 ↗ NCT01364675 ↗ NCT01110824 ↗ NCT02554890 ↗ NCT01968200 ↗ NCT07363343 ↗ NCT02970669 ↗ NCT02768298 ↗ NCT01115946 ↗ NCT01211314 ↗ NCT01754909 ↗ NCT00235287 ↗ NCT04912167 ↗ NCT03179163 ↗ NCT01093807 ↗ NCT00391846 ↗ NCT07568574 ↗ NCT02678312 ↗ NCT00484068 ↗ NCT01035255 ↗ NCT00895414 ↗ NCT00882440 ↗ NCT03066804 ↗ NCT00543413 ↗ NCT02252692 ↗ NCT01117038 ↗ NCT02623036 ↗ NCT02135263 ↗ NCT02874794 ↗ NCT00000516 ↗ NCT00734123 ↗ NCT03526042 ↗ NCT03051282 ↗ NCT01007994 ↗ NCT00520247 ↗ NCT00666848 ↗ NCT03190304 ↗ NCT00004328 ↗ NCT03265574 ↗ NCT03005184 ↗ NCT03917459 ↗ NCT00000522 ↗ NCT06788314 ↗ NCT02432885 ↗ NCT01891292 ↗ NCT01041963 ↗ NCT02654678 ↗ NCT00568178 ↗ NCT07023003 ↗ NCT05487261 ↗ NCT00853658 ↗ NCT00456963 ↗ NCT01437371 ↗ NCT00143949 ↗ NCT03667131 ↗ NCT01305850 ↗ NCT00113087 ↗ NCT00394394 ↗ NCT00302705 ↗ NCT02281838 ↗ NCT00003070 ↗ NCT00367562 ↗ NCT01705392 ↗ NCT00274118 ↗ NCT00000547 ↗ NCT07222852 ↗ NCT00141583 ↗ NCT02214498 ↗ NCT04183101 ↗ NCT04853758 ↗ NCT01151410 ↗ NCT06187493 ↗
Known as	Corodil	“Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response” NCT03949075 ↗
Known as	Enalapril "ratiopharm"	“enalapril (Enalapril "ratiopharm") 10mg” NCT06710600 ↗
Known as	enalapril maleate	“The PROACT trial will establish the effectiveness of the ACE inhibitor enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and...” PMID 36585130 ↗ Dec 2022 4 “Drug: enalapril maleate” NCT00003070 ↗ NCT05711810 ↗ NCT01871740 ↗ NCT02575092 ↗
Known as	Epaned	“Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗
Known as	Vasotec	“Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗
Action	Inhibit	“SOLVD was initiated in 1986 primarily to evaluate the effects of enalapril, an angiotensin-converting enzyme (ACE) inhibitor.” NCT00000516 ↗
Modality	Other / unclassified	“an ACE Inhibitor” NCT03119623 ↗
Route	Oral	“Patients are administered enalapril or placebo by mouth bid.” NCT00003070 ↗
Target	ACE	“SOLVD was initiated in 1986 primarily to evaluate the effects of enalapril, an angiotensin-converting enzyme (ACE) inhibitor.” NCT00000516 ↗